JPRN-UMIN000009136已完成4 期
Short term clinical efficacy and safety of Tolvaptan additional treatment compared with escalation treatment of conventional diuretics in HF patients with volume overload despite treatments with the conventional diuretics - Short term clinical efficacy and safety of Tolvaptan additional treatment compared with dose up conventional diuretics treatment in HF patients with volume overload despite the treatment with the conventional diuretics
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with a history of hypersensitivity for an ingredient of tolvaptan or an analogue (Mozavaptan) Patients with anuria Patients who cannot feel thirst or are difficult to intake the fluid. Patients with hypernatremia. Female patients who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant. Patients who are diagnosed following diseases A)Serious coronary artery disease, cerebrovascular disease B)Hyperkalemia C)Serious Renal failure D)Diabetes mellitus with poorly controlled blood glucose E)Serious hepatic disorder F)Urinary excretion disorder in order to the stenosis of the urinary tract G)Valvular disease that in order to valvular stenosis is severe H)Malignant tumor Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study.
研究者
相似试验
已完成
不适用
ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease PatientsAutosomal Dominant Polycystic Kidney DiseaseJPRN-UMIN000021267Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine119
尚未招募
4 期
A study on the safety and efficasy of tolvaptan for patients with fluid retention after cardiothoracic surgeryPatients received cardiothoracic surgery with congestive heart failure.JPRN-UMIN000011172Osaka city university graduate school of medicine210
招募中
不适用
A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.ephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneJPRN-UMIN000021708Department of Nephrology and Endocrinology, The University of Tokyo Hospital3
已完成
不适用
ong-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failureheart failureJPRN-UMIN000013807ihon University Surugadai Hospital100
已完成
不适用
Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertensiopulmonary hypertensionJPRN-UMIN000010196Department of Cardiology, Keio University School of Medicine40